Catalyst Wire Dossier Catalyst Wire Dossier

bemcentinib (BGB324)

bemcentinib · BerGenBio ASA
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for bemcentinib (BGB324), covering 2025-01-29 to 2025-09-25. Get the full timeline:

Most recent: Clinical Trial Update: Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 2]

See pricing